News
Intellia's Data Reveal Tees Up FDA Filing for CRISPR-Based In Vivo Gene-Editing Med
4+ week, 1+ day ago (247+ words) Intellia Therapeutics" lonvo-z uses CRISPR to inactivate a gene in the liver to reduce levels of a protein key to the swelling attacks from the rare disease hereditary angioedema. Intellia has filed a regulatory submission for this genetic medicine, which…...
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
1+ mon, 1+ hour ago (449+ words) Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U. S. Food and…...
Gene-editing cholesterol away, new Alzheimer's findings and a supplement warning
1+ day, 2+ hour ago (383+ words) A single infusion. A dramatic drop in bad cholesterol. And results that may last a lifetime. An experimental gene-editing treatment is turning heads in the medical world " and researchers say it could one day change the way heart'disease is prevented…...
Southeast Asian Hospital Teams Strengthen Efforts to Combat Antimicrobial Resistance
4+ hour, 25+ min ago (251+ words) Southeast Asia is among the global regions with the highest CRO burden. In 2021, between 8, 300 to 21, 800 deaths in the region were attributable to CROs. [[1]] To help address this challenge, CDC hosted a regional workshop in Bangkok, Thailand in December 2024 to improve…...
Al-Ola A Abdallah Comments On the New Article on Dual-Target CAR-T Strikes Hard in EMD - Onco Daily
17+ hour, 56+ min ago (269+ words) Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on'X: "Dual-Target CAR-T Strikes Hard in EMD: ORR 97%, PFS 6 months! Is Persistence the Missing…...
Breeze Bio Announces Scientific Advisory Board to Support Next Stage of Precision Genetic Medicine Pipeline Development
1+ day, 1+ hour ago (523+ words) Bio Space Breeze Bio Announces Scientific Advisory Board to Support Next Stage of Precision Genetic Medicine Pipeline Development SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--#Nano Galaxy--Breeze Bio, Inc. , formerly known as Gen Edit, today announced the formation of its…...
One-time gene editing cuts LDL cholesterol in early hypercholesterolemia trial
17+ hour, 45+ min ago (483+ words) A single infusion of VERVE-102 sharply lowered PCSK9 and LDL cholesterol in a small phase 1 trial, offering early evidence for a potentially durable genetic approach to cholesterol control, while long-term safety and clinical benefit remain to be proven. Study: In Vivo…...
Eli Lilly Gene Therapy Cuts Cholesterol Dramatically in Early Trial
13+ hour, 56+ min ago (63+ words) Whalesbook Eli Lilly's gene-editing therapy VERVE-102 has shown impressive early results, cutting LDL-C by 62% and PCSK9 protein by 88% in a Phase 1b trial. This one-time treatment, acquired from Verve Therapeutics, aims to offer a permanent solution for high cholesterol patients, reducing the…...
Can an injection prevent heart attacks? Eli Lilly's gene-editing therapy cuts LDL cholesterol by 62%
18+ hour, 23+ min ago (279+ words) In an early-stage clinical trial, published in "The New England Journal of Medicine" and presented at the European Atherosclerosis Society Congress this week, researchers reported that a single infusion of a gene-editing therapy called VERVE-102 sharply lowered LDL cholesterol by…...
Cholesterol-Lowering Gene Therapy Trial Begins in Victoria 27 May
21+ hour, 34+ min ago (476+ words) Professor Stephen Nicholls, Director of the Victorian Heart Hospital and Victorian Heart Institute, and Professor of Cardiology at Monash University, is Principal Investigator of a first-in-human trial that could significantly change how we manage cardiovascular risk in the future. The…...